| Patented Medicine Prices Review Board Canada | news releases
The Patented Medicine Prices Review Board (PMPRB) will launch the first phase of consultations on its new Guidelines by inviting stakeholders to participate in a Policy Roundtable.
| Patented Medicine Prices Review Board Canada | news releases
The Patented Medicine Prices Review Board (PMPRB) published today the 7th edition of its annual Meds Entry Watch report.
| Patented Medicine Prices Review Board Canada | news releases
Oncology continued to dominate the therapeutic mix of the drug pipeline in 2022.
| Patented Medicine Prices Review Board Canada | news releases
PMPRB consults on new proposed Interim Guidance
| Patented Medicine Prices Review Board Canada | news releases
Canadian prices for top-selling antidiabetic drugs were higher than those in the PMPRB’s comparator countries from 2012 to 2021.
| Patented Medicine Prices Review Board Canada | news releases
The Government of Canada is seeking applicants for the Vice Chairperson position and two Board Member positions on the Patented Medicine Prices Review Board by way of open, transparent, and merit-based Governor in Council selection processes.
| Patented Medicine Prices Review Board Canada | news releases
Douglas Clark, Executive Director of the Patented Medicine Prices Review Board (PMPRB), has announced that he will be stepping down from that position after almost a decade at the PMPRB.
| Patented Medicine Prices Review Board Canada | news releases
A new Patented Medicine Prices Review Board (PMPRB) report finds that prescription drug expenditures by Canadian public drug plans increased by 4.2% in 2020-21, bringing annual spending to $12.3 billion.
| Patented Medicine Prices Review Board Canada | news releases
The Honourable Jean-Yves Duclos, Federal Minister of Health, tabled the 2021 Annual Report of the Patented Medicine Prices Review Board with the Clerks of the Senate and the House of Commons on Friday.
| Patented Medicine Prices Review Board Canada | news releases
In an order dated October 13, 2022, the Hearing Panel directed Horizon to pay $22,028,977.26 to the Receiver General of Canada within 30 days of the date of the Order. It is the largest amount ever ordered by the Board in an excessive price hearing.
